Endocrine Abstracts

Introduction: There is currently high interest in the non-glycemic effects of incretin-based therapies, specifically glucagon-like peptide 1 (GLP-1) analogues, such as those on cardiovascular system. Liraglutide has been approved in Italy since one year to be prescribed in combination with oral hypoglycemic agents; it has several non-glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown...

Introduction: Liraglutide exerts cardio-protective effects beyond of those on glucose metabolism, affecting several cardio-metabolic parameters, such as subclinical atherosclerosis. However, it is not known if those effects differ in the long-term between pre-elderly and elderly subjects with type-2 diabetes (T2DM).Methods: We included 135 subjects with T2DM divided in 2 groups: i) 71 pre-elderly subjects (46 men and 25 women, 55±7 years), and ii) 6...

Background: The presence of the metabolic syndrome (MS) increases cardiovascular morbidity and mortality but few data is available on the outcome in subjects with the MS and subclinical atherosclerosis.Aim: We aimed to assess cardio- and cerebro-vascular events in subjects with MS and subclinical atherosclerosis.Methods: We followed-up for 5 years 339 subjects with asymptomatic carotid intima-media thickness >0.9 mm, of whom 13...